Human epidermal growth factor receptor 2 (HER2)‐targeted therapies, e.g., trastuzumab, have revolutionized the treatment of HER2‐positive breast cancer, yet researches were deterred by cardiopulmonary toxicities due to the expression of HER2 in cardiomyocytes and bronchial epithelial cells, and such toxicity issues are even worsened in patients with concurrent chemotherapy.[22] Exhilaratingly, the INTACT strategy also realized successful toxicity reduction of HER2 antibodies, indicating extended applicability for antibodies with different targets. Here, ERBB2 is linked to breast cancer.